Clinical study of nalbuphine combined with hydromorphone for PCIA analgesia after gynecological laparoscopic surgery

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1800017188

Enrollment

Unknown

Registered

2018-07-17

Start date

2018-07-18

Completion date

Unknown

Last updated

2018-07-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gynecological laparoscopic analgesia

Interventions

1:(0.8mg/ml nalbuphine + 0.1mg/ml dexamethasone+ saline)/100ml PCIA

2:(0.6mg/ml nalbuphine+ 0.02mg/ml hydromorphone + 0.1mg/ml dexamethasone+ saline)/100ml PCIA

3:(0.4mg/ml nalbuphine+ 0.04mg/ml hydromorphone + 0.1mg/ml dexamethasone+ saline)/100ml PCIA

4:(0.2mg/ml nalbuphine+ 0.06mg/ml hydromorphone + 0.1mg/ml dexamethasone+ saline)/100ml PCIA

5:(0.08mg/ml hydromorphone + 0.1mg/ml dexamethasone+ saline)/100ml PCIA

Eligibility

Sex/Gender

Female

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. female patients undergoing gynaecologic surgery (total abdominal hysterectomy, myomectomy, and excision of ovarian tumour); 2. ASA I or II; 3. aged 18-65 years old; 4. BMI 19-29kg/m2; 5. without history of drug abuse, chronic pain, or psychiatric disorders.

Exclusion criteria

Exclusion criteria: 1. Patients who took opioids in the past 3 months; 2. Pruritus history after operation; 3. Poor compliance, unable to complete the research plan; 4. Has participated in clinical drug trials in the past 3 months.

Design outcomes

Primary

Measure	Time frame
VAS;	—

Secondary

Measure	Time frame
The total consumption of PCIA;Nausea & vomiting;Dizziness & drowsiness;pruritus;	—

Countries

China

Contacts

Public ContactYanqiu Ai

The First Affliated Hospital of Zhengzhou University

aiyanqiu82@163.com+86 13607690334

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026